Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 03:30PM GMT
Release Date Price: $23.5 (-8.81%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Good morning, everyone, for 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the Senior Large-cap Biotech Analyst, and it's my pleasure to introduce Editas Medicine, and Chairman and CEO, Jim Mullen.

Please note that following the presentation, we will move right into a Q&A session, where you can send in your questions via the conference portal, and I'll do my best to work them into the conversation.

So with that, Jim, thanks, as always, for joining us today, and let me turn things over to you for an update on Editas.

James C. Mullen
Editas Medicine, Inc. - Chairman, President & CEO

Thank you, Cory, for the introduction. And to everyone, welcome to the Editas Medicine presentation. I was appointed as CEO 11 months ago, and at that time, I had a few objectives.

The first was to assess our science and the evolution of the science and gene editing, where is our technology differentiated and where should we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot